Literature DB >> 26806094

Role of NLRC5 in progression and reversal of hepatic fibrosis.

Xuejiao Liu1, Yuting Wu2, Yang Yang2, Wanxia Li2, Cheng Huang2, Xiaoming Meng2, Jun Li3.   

Abstract

BACKGROUND: NLRC5, as the largest member of NLRs family, has recently been identified as a critical regulator of immune responses through negatively regulating NF-κB which is associated with the development of hepatic fibrosis. However, the expression and potential roles of NLRC5 in hepatic fibrosis and its reversal are still to be defined.
METHODS: C57BL/6 mice were treatment with carbon tetrachloride (CCl4) induce hepatic fibrosis and its reversal. In vitro, models of hepatic fibrosis and its reversal are established by the treatment with TGF-β and MDI. The expression of NLRC5 was determined by RT-PCR, Western blot and immunohistochemistry. Consequently, NLRC5 was overexpressed or knockdown by transfecting PEGFP-C2-NLRC5 or NLRC5-siRNA respectively in the reversal of hepatic fibrosis, and the expression of fibrogenic genes such as α-SMA and Col1α1 was quantified. The NF-κB activity was detected as well.
RESULTS: Immunohistochemistry, RT-PCR and Western blot analysis with liver tissues and primary HSCs showed that NLRC5 was highly expressed in hepatic fibrosis and correspondingly decreased in the reversal stage. The differential expression of NLRC5 was confirmed in vitro. Enforced NLRC5 expression increased the expression of α-SMA and Col1α1, and blockade of NLRC5 reduced the fibrotic response. While the opposite expression of phosphorylated NF-кB p65 and phospho-IκBα was found.
CONCLUSION: NLRC5 is differentially expressed in hepatic tissues and hepatic stellate cells during hepatic fibrosis and its reversal. All the data indicated that NLRC5 may play a crucial role in regulating the reversal of hepatic fibrosis through NF-κB signaling pathway.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  HSCs reversion; Hepatic fibrosis; NLRC5; Reversal of hepatic fibrosis

Mesh:

Substances:

Year:  2016        PMID: 26806094     DOI: 10.1016/j.taap.2016.01.012

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  12 in total

Review 1.  siRNA- and miRNA-based therapeutics for liver fibrosis.

Authors:  Zhen Zhao; Chien-Yu Lin; Kun Cheng
Journal:  Transl Res       Date:  2019-08-13       Impact factor: 7.012

2.  Imidazoline I2 receptor inhibitor idazoxan regulates the progression of hepatic fibrosis via Akt-Nrf2-Smad2/3 signaling pathway.

Authors:  Li Xuanfei; Chen Hao; Yi Zhujun; Liu Yanming; Gong Jianping
Journal:  Oncotarget       Date:  2017-03-28

Review 3.  NLRC5 Functions beyond MHC I Regulation-What Do We Know So Far?

Authors:  Szilvia Benkő; Elek Gergő Kovács; Felix Hezel; Thomas A Kufer
Journal:  Front Immunol       Date:  2017-02-17       Impact factor: 7.561

4.  Circular RNA circFBXW4 suppresses hepatic fibrosis via targeting the miR-18b-3p/FBXW7 axis.

Authors:  Xin Chen; Hai-Di Li; Fang-Tian Bu; Xiao-Feng Li; Yu Chen; Sai Zhu; Jia-Nan Wang; Si-Yu Chen; Ying-Yin Sun; Xue-Yin Pan; Na-Na Yin; Jie-Jie Xu; Cheng Huang; Jun Li
Journal:  Theranostics       Date:  2020-03-26       Impact factor: 11.556

5.  NLRC5 Deficiency Deregulates Hepatic Inflammatory Response but Does Not Aggravate Carbon Tetrachloride-Induced Liver Fibrosis.

Authors:  Akouavi Julite I Quenum; Akhil Shukla; Fjolla Rexhepi; Maryse Cloutier; Amit Ghosh; Thomas A Kufer; Sheela Ramanathan; Subburaj Ilangumaran
Journal:  Front Immunol       Date:  2021-10-12       Impact factor: 7.561

Review 6.  Therapeutic and diagnostic targeting of fibrosis in metabolic, proliferative and viral disorders.

Authors:  Alexandros Marios Sofias; Federica De Lorenzi; Quim Peña; Armin Azadkhah Shalmani; Mihael Vucur; Jiong-Wei Wang; Fabian Kiessling; Yang Shi; Lorena Consolino; Gert Storm; Twan Lammers
Journal:  Adv Drug Deliv Rev       Date:  2021-06-15       Impact factor: 15.470

Review 7.  Inflammasomes and Fibrosis.

Authors:  Wen-Juan Zhang; Shu-Juan Chen; Shun-Chang Zhou; Su-Zhen Wu; Hui Wang
Journal:  Front Immunol       Date:  2021-06-11       Impact factor: 7.561

8.  The Long Non-coding RNA MEG3/miR-let-7c-5p Axis Regulates Ethanol-Induced Hepatic Steatosis and Apoptosis by Targeting NLRC5.

Authors:  Qin Wang; Mingfang Li; Zhiming Shen; Fangtian Bu; Haixia Yu; Xueyin Pan; Yang Yang; Xiaoming Meng; Cheng Huang; Jun Li
Journal:  Front Pharmacol       Date:  2018-04-10       Impact factor: 5.810

9.  NLRC5: potential novel non-invasive biomarker for predicting and reflecting the progression of IgA nephritis.

Authors:  Yusa Chen; Huihui Li; Chenggen Xiao; Xiangli Zeng; Xiangcheng Xiao; Qiaoling Zhou; Ping Xiao
Journal:  J Transl Med       Date:  2018-11-19       Impact factor: 5.531

10.  NLRC5 regulates expression of MHC-I and provides a target for anti-tumor immunity in transmissible cancers.

Authors:  Chrissie E B Ong; Amanda L Patchett; Jocelyn M Darby; Jinying Chen; Guei-Sheung Liu; A Bruce Lyons; Gregory M Woods; Andrew S Flies
Journal:  J Cancer Res Clin Oncol       Date:  2021-04-02       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.